2 results match your criteria serendipitously hsp90

  • Page 1 of 1

Making HSP90 Inhibitors Great Again? Unite for Better Cancer Immunotherapy.

Authors:
Michael W Graner

Cell Chem Biol 2021 Feb;28(2):118-120

Department of Neurosurgery, University of Colorado, Anschutz Medical Campus, Aurora, CO 80045, USA. Electronic address:

HSP90 inhibitors are in numerous cancer clinical trials, but treatments often induce toxicity at effective dosages. In this issue of Cell Chemical Biology, Zavareh et al. (2020) serendipitously found that HSP90 inhibitors, at manageable doses, can reduce target cell expression of immune checkpoint molecules, potentially enabling improved anti-cancer immunotherapy. Read More

View Article and Full-Text PDF
February 2021

Clinical use of crizotinib for the treatment of non-small cell lung cancer.

Biologics 2013 26;7:91-101. Epub 2013 Apr 26.

Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

Discoveries over the last decade have fundamentally transformed the way we define lung cancer. Gone are the days of the simple binary classification system of non-small cell lung cancer (NSCLC) and small cell lung cancer. Today, accurate identification of the histological and molecular subtype of NSCLC is required for selecting standard cytotoxic chemotherapy and targeted therapies. Read More

View Article and Full-Text PDF
  • Page 1 of 1